Torsten Dahlén
Torsten Dahlén
Verified email at ki.se
Title
Cited by
Cited by
Year
Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study
T Dahlén, G Edgren, M Lambe, M Höglund, M Björkholm, F Sandin, ...
Annals of internal medicine 165 (3), 161-166, 2016
68*2016
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era–a report from the Swedish CML register
S Söderlund, T Dahlén, F Sandin, U Olsson‐Strömberg, M Creignou, ...
European journal of haematology 98 (1), 57-66, 2017
162017
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving …
T Dahlén, M Kalin, K Cederlund, A Nordlander, M Björkholm, P Ljungman, ...
European journal of haematology 96 (2), 175-180, 2016
152016
Increased risk of cardiovascular events associated with TKI treatment in chronic phase chronic myeloid leukemia. Data from Swedish population-based registries
T Dahlén, G Edgren, M Höglund, M Lambe, M Björkholm, F Sandin, ...
Blood, The Journal of the American Society of Hematology 124 (21), 3134-3134, 2014
92014
Estimating heritability and genetic correlations from large health datasets in the absence of genetic data
G Jia, Y Li, H Zhang, I Chattopadhyay, AB Jensen, DR Blair, L Davis, ...
Nature communications 10 (1), 1-11, 2019
62019
Measurable health effects associated with the daylight saving time shift
H Zhang, T Dahlén, A Khan, G Edgren, A Rzhetsky
PLoS computational biology 16 (6), e1007927, 2020
42020
Risk of hematological malignancy in blood donors: a nationwide cohort study
Z Jingcheng, D Torsten, B Anne, E Gustaf
Transfusion, 2020
22020
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic …
C Hirt, S Iannazzo, S Chiroli, LJ McGarry, P le Coutre, L Stenke, T Dahlén, ...
Applied health economics and health policy 17 (4), 555-567, 2019
22019
An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk
T Dahlén, M Clements, J Zhao, ML Olsson, G Edgren
bioRxiv, 2021
12021
Costs associated with transfusion therapy in patients with myelodysplastic syndromes in Sweden: a nationwide retrospective cohort study
J Zhao, T Dahlén, G Edgren
Vox sanguinis, 2020
12020
Successful tyrosine kinase inhibitor discontinuation outside clinical trials—data from the population‐based Swedish chronic myeloid leukaemia registry
H Flygt, F Sandin, T Dahlén, A Dremaine, A Lübking, B Markevärn, ...
British Journal of Haematology, 2021
2021
TCT CONNECT-82 Prognostic Value of Serial Neutrophil-to-Lymphocyte Ratio in Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement: The PARTNER I-II Trials and …
B Shahim, B Redfors, S Chen, T Dahlen, B Lindman, S Kapadia, Z Gertz, ...
Journal of the American College of Cardiology 76 (17 Supplement S), B36-B37, 2020
2020
jiagengjie/Estimating-Genetic-Parameters
G Jia, Y Li, H Zhang, I Chattopadhyay, A Boeck Jensen, DR Blair, L Davis, ...
Github, 2019
2019
Progression of chronic phase chronic myeloid leukemia to advanced phase on tki therapy: A population based analysis from the Swedish CML register
S Soderlund, T Dahlen, M Creignou, F Sandin, U Olsson-Stromberg, ...
Haematologica 100, 233-233, 2015
2015
Supplementary Materials for “Measurable Health Effects Associated with the Daylight Saving Time Shift”
H Zhang, T Dahlén, A Khan, G Edgren, A Rzhetsky
The system can't perform the operation now. Try again later.
Articles 1–15